Study of QLS1410 in the Treatment of Primary Aldosteronism.

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Primary Aldosteronism

In brief

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, and efficacy of QLS1410 versus placebo, on the reduction of Seated Blood Pressure (SBP) in participants ≥ 18 years of age with Primary Aldosteronism (PA) with or without prior treatment with Mineralocorticoid Receptor Antagonists (MRAs) or potassium-sparing diuretics. QLS1410 (or placebo) will be administered once daily, up-titrated after 2 weeks or 4 weeks based on clinical response and tolerability.

Key facts

Study ID
NCT07550465
Run by
Qilu Pharmaceutical Co., Ltd.
People needed
60
Starts
2026-06-01
Expected to finish
2027-04-01
Last updated by the study team
2026-04-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.